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Abstract
Background: Effective strategies are needed for the prevention of mother-to-child HIV transmission (PMTCT) in resource-
limited settings. The Kisumu Breastfeeding Study was a single-arm open label trial conducted between July 2003 and
February 2009. The overall aim was to investigate whether a maternal triple-antiretroviral regimen that was designed to
maximally suppress viral load in late pregnancy and the first 6 mo of lactation was a safe, well-tolerated, and effective
PMTCT intervention.
Methods and Findings: HIV-infected pregnant women took zidovudine, lamivudine, and either nevirapine or nelfinavir from
34–36 weeks’ gestation to 6 mo post partum. Infants received single-dose nevirapine at birth. Women were advised to
breastfeed exclusively and wean rapidly just before 6 mo. Using Kaplan-Meier methods we estimated HIV-transmission and
death rates from delivery to 24 mo. We compared HIV-transmission rates among subgroups defined by maternal risk
factors, including baseline CD4 cell count and viral load. Among 487 live-born, singleton, or first-born infants, cumulative
HIV-transmission rates at birth, 6 weeks, and 6, 12, and 24 mo were 2.5%, 4.2%, 5.0%, 5.7%, and 7.0%, respectively. The 24-
mo HIV-transmission rates stratified by baseline maternal CD4 cell count ,500 and $500 cells/mm
3 were 8.4% (95%
confidence interval [CI] 5.8%–12.0%) and 4.1% (1.8%–8.8%), respectively (p=0.06); the corresponding rates stratified by
baseline maternal viral load ,10,000 and $10,000 copies/ml were 3.0% (1.1%–7.8%) and 8.7% (6.1%–12.3%), respectively
(p=0.01). None of the 12 maternal and 51 infant deaths (including two second-born infants) were attributed to
antiretrovirals. The cumulative HIV-transmission or death rate at 24 mo was 15.7% (95% CI 12.7%–19.4%).
Conclusions: This trial shows that a maternal triple-antiretroviral regimen from late pregnancy through 6 months of
breastfeeding for PMTCT is safe and feasible in a resource-limited setting. These findings are consistent with those from
other trials using maternal triple-antiretroviral regimens during breastfeeding in comparable settings.
Trial registration: ClinicalTrials.gov NCT00146380
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UNAIDS and the World Health Organization (WHO) estimate
that in 2009 there were 230,000 to 510,000 new HIV infections
worldwide among children aged 0–15 y of age [1]. Over 95% of
these infections occurred in resource-limited settings, primarily
sub-Saharan Africa. Most infections resulted from mother-to-child
transmission (MTCT). HIV MTCT rates in the absence of any
antiretroviral (ARV) intervention among breastfeeding mothers
who tested HIV antibody positive during pregnancy or delivery
have ranged from 25% to 48% in various studies [2]. Breastfeed-
ing, which is crucial to infant survival in resource-limited settings,
accounts for one-third to one-half of MTCT [3–5]. Several trials
of short-course/single-dose peripartum ARV regimens have
reported 18-mo transmission rates between 6.8% and 15.9% [6–
8]. However, in most of these studies, transmission events occurred
while the infants were breastfeeding and not prophylaxed by
maternal or infant ARVs [9].
For HIV-infected pregnant women in situations where
replacement infant foods are not affordable, feasible, accessible,
safe, and sustainable (AFASS conditions), 1998 WHO guidelines
[10] encouraged exclusive breastfeeding for the first months of life
followed by rapid weaning. Revised 2006 guidelines [11]
recommended that AFASS conditions should be reassessed with
the mother at 6 mo, and if not met, breastfeeding should continue
with the introduction of complementary feeding.
In recognition of both the benefits and risks of breastfeeding for
HIV-exposed infants, several trials have been conducted over the
last decade to assess the impact on prevention of MTCT
(PMTCT) of various combinations of ARV regimens given to
mother and/or infant. We conducted the Kisumu Breastfeeding
Study (KiBS) in Kisumu, Kenya; a PMTCT single-arm trial using
a maternal triple-ARV regimen given to HIV-infected pregnant
women beginning at 34 wk gestation and continuing for up to
6 mo post partum while exclusively breastfeeding. The primary
objective of this trial was to assess whether the regimen was
feasible, well tolerated, safe, and achieved a lower transmission
rate compared to other short-course regimens evaluated among
breastfeeding mothers in resource-limited settings.
Methods
KiBS was a phase IIB open-label single-arm clinical/interven-
tion trial approved by the ethical review committees of KEMRI
(protocol 691) and US CDC (protocol 3677). See Protocol (Text
S1) and CONSORT statement (Text S2).
Primary Objectives
The primary objectives of this study using maternal triple-ARV
for PMTCT in late pregnancy and during breast feeding were the
following: (1) to detect a 50% reduction in the mother-to-child
HIV-transmission rate at 18 mo compared to the corresponding
rate using the single-dose nevirapine (NVP) regimen in the
HIVNET 012 study [8]; (2) to detect a 50% improvement in the
infant HIV-free survival rate at 18 mo compared to the
corresponding rate using the single-dose NVP regimen in the
HIVNET 012 study [8]; (3) to assess safety and toxicity for the
mothers with use of the maternal triple-ARV prophylaxis
particularly regarding rates of hepatic, hematologic, or dermato-
logic toxicities; (4) to assess adverse events or evidence of hepatic,
hematologic, or dermatologic toxicity for infants exposed to low
dose ARVs through maternal breast milk.
Participants
Enrollment was conducted between July 2003 and November
2006; follow-up was completed in February 2009. Women were
recruited through the PMTCT programs in the antenatal clinics of
the New Nyanza Provincial General Hospital and the Kisumu
District Hospital, both serving lower income populations of
Kisumu and its environs. Pregnant women were invited to enroll
if they were HIV positive and if, after receiving risk-benefit
counseling on infant feeding options, they indicated intent to
breastfeed. Enrollment criteria included: age $15 y, gestation of
34–36 wk, no previous ARV exposure, hemoglobin (Hb) $7 g/dl,
absolute neutrophil count (ANC) .1,000 cells/mm
3, platelets
.50,000/ml, creatinine ,1.5 mg/dl, and serum alanine amino-
transferase (ALT) ,2.5 times upper limit of normal.
Procedures
Potential participants provided written informed consent, and at
32–34 wk gestation they underwent screening evaluations, which
included a medical history, a physical examination, laboratory
confirmation of HIV status, complete blood count, CD4 cell
count, creatinine, and ALT tests. Participants started the triple-
ARV regimen at 34–36 wk gestation and continued while
breastfeeding, until 6 mo post partum. The initial regimen
consisted of two nucleoside reverse transcriptase inhibitors and a
non-nucleoside reverse transcriptase inhibitor. Between July 2003
and January 2005, regardless of CD4 cell count, mothers received
zidovudine (ZDV) 300 mg and lamivudine (3TC) 150 mg in a
fixed-dose combination pill (Combivir, GlaxoSmithKline), taken
twice daily, and NVP 200 mg (Viramune, Boehringer Ingelheim),
once daily for the first 2 wk and then twice daily thereafter. In
January 2005, enrollment was halted because of reports of
hepatotoxicity among women who started taking NVP when their
CD4 count was $250 cells/mm
3 [12]. Enrollment resumed in July
2005 with a revised regimen; women with a baseline CD4 count of
$250 cells/mm
3 received nelfinavir (NFV) (Viracept, Hoffman-La
Roche Ltd) 1,250 mg (five 250 mg pills) twice daily instead of
NVP. The decision to use NFV as an alternative ARV was based
on the safety data available at that time and appropriateness of use
in resource-limited settings. All women who met WHO treatment
criteria (CD4 count of ,200 cells/mm
3 or WHO stage 3 or 4) [13]
at enrollment or before 6 mo post partum remained on ARVs
throughout the study; those who subsequently met WHO
treatment criteria after stopping ARVs at 6 mo were restarted
on treatment ARVs. Upon exiting the study, all participants were
referred to facilities providing HIV care and treatment, including
free ARVs. All women received trimethoprim-sulfamethoxazole
(TMP/SMX) for prophylaxis of opportunistic infections through-
out the study, except from 38 wk gestation until delivery because
of concerns about neonatal hyperbilirubinemia.
Infants received single dose NVP (2 mg/kg) within 72 h of birth
and TMP/SMX from 6 wk of age until they were no longer
exposed to HIV through breastfeeding and were confirmed to be
HIV negative. HIV-infected infants began ARV treatment when
they met WHO infant treatment criteria [13].
Women were counseled to exclusively breastfeed for the first
5.5 mo and then to wean over 2 wk, with complete cessation of
breastfeeding by 6 mo. We encouraged use of locally available
foods (e.g., porridge, soups), and cow’s milk for weaning and
replacement feeding. We did not consider evaluating formula as a
PMTCT intervention in accordance with guidance from the
Provincial Ministry of Health about the risks of formula feeding,
and in light of evidence of poor acceptance of free formula
provided by UNICEF in Kenya [14].
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delivery, each mother and her infant(s) were followed for 24 mo:
study visits were scheduled at delivery (0–7 d), 2, 6, 10, and 14 wk
post partum, and 6, 9, 12, 15, 18, and 24 mo post partum. Three
visits were added at 5, 7, and 8 mo to monitor infant weight
around weaning. During study visits, we assessed adherence to
drugs and infant feeding recommendations, performed clinical
evaluations, and obtained blood for hematologic, biochemical, and
virologic monitoring. Adherence to study ARVs was assessed
through pill counts, calculated as the percentage of pills dispensed
but not returned out of the total number of pills dispensed. The
study provided or covered the cost for all outpatient and inpatient
care required by participants while on study.
All laboratory testing was done at the KEMRI/CDC laboratory
in Kisumu. Hematologic testing was done using a Coulter A
c.T
5diff CP analyzer (Beckman Coulter). Lymphocyte subsets were
analyzed on a FACSCalibur flow cytometer (Becton Dickinson).
Biochemistry analysis was done using the Cobas Integra 400 plus
biochemistry analyzer (Roche). Plasma viral loads were quantified
using the Amplicor HIV-1 RNA Monitor Test v1.5 (Roche
Diagnostics). HIV DNA testing by PCR was done using Amplicor
HIV-1 DNA PCR assay v1.5 (Roche Diagnostics). ELISA was
done using Vironostika HIV Uniform II plus O kit (Organon
Teknika) and Enzygnost (Dade Behring Marburg GmbH).
For HIV testing of infants we used dried blood spots collected at
birth (0–7 d), at 2, 6, and 14 wk, and at 6, 9, 12, 18, and 24 mo.
DNA PCR testing was performed in real time on the 14-wk and 6-
and 9-mo specimens. ELISA was performed at 18 and 24 mo,
with confirmation of positive results by PCR. After any positive
test result, PCR testing was performed sequentially on prior
untested specimens in order to identify the first positive specimen.
We graded adverse events according to the 1992 Adult and
1994 Pediatric toxicity tables [15,16] of the Division of AIDS
(DAIDS), US National Institutes of Health (NIH). Serious adverse
events (SAEs) were defined as grade 3 or 4 toxicity confirmed on a
repeat visit or as illness resulting in death or hospitalization. In
addition, grade 2 hepatotoxicity events and grade 2 rashes with
signs of hypersensitivity reaction were classified as SAEs. SAEs
that occurred while participants were taking ARVs or within 3 mo
of their cessation were considered possibly related to an ARV if an
increased risk was noted in the prescribing information for the
drug [17,18] or if no alternative cause could be found. We did not
rechallenge participants with the potentially causative ARV. We
confine this analysis to those SAEs occurring between enrollment
and 9 mo post partum. Abnormal laboratory findings were
confirmed prior to any change in ARV regimen. Causes of death
were determined by review of hospital records (if available) and/or
by interviewing the mother, spouse, or caretaker (verbal autopsy).
Statistical Analysis
We performed a series of sample size and power calculations
under a variety of assumptions. Historically, the cumulative HIV-
transmission rate in the NVP arm of the HIVNET 012 study [8]
was 11.8% at 6 wk and 15.7% at 18 mo of age. We wanted to be
able to detect a 50% reduction in the corresponding rate in KiBS
using a one-sided exact binomial test at the 0.025 significance
level, as an approximation to the test based on the Kaplan-Meier
function for low rates. For 95% statistical power, if the true HIV-
transmission rate in KiBS was 8%, 9%, or 10%, then 225, 305, or
425 children, respectively, would be needed for analysis at 18 mo
of age. We further inflated these sample sizes by a factor of
1/(120.2) to account for maternal and child drop-out, as well as
other sources of heterogeneity, thus giving a required maternal
enrolment of 282, 382, or 532, respectively. Standard summary
statistics were used to describe sociodemographic, clinical,
laboratory, delivery, and adherence data. All statistical calculations
were performed using SAS statistical software (SAS Institute).
For the evaluation of HIV transmission we included only live-
born singleton or first-born infants who had any HIV test data.
For our purposes, ‘‘first-born’’ means the first infant born in a
multiple birth (e.g., the first twin). For infants testing HIV positive,
the time of HIV transmission was estimated as the midpoint
between the last negative and first positive test result. All infants
with PCR-positive samples before 7 d of age were assumed to have
been born infected. We used the Kaplan-Meier method to
estimate HIV-transmission rates, death rates, and combined
HIV-transmission or death rates over the 2-y follow-up period,
and constructed 95% confidence interval (CIs) using the log-log
transformation. We included all infants regardless of maternal
adherence to intervention or maternal death. Serial pregnancies
were not included.
For the HIV-transmission analysis, the endpoint was the
estimated time of HIV transmission or was censored at the last
negative test result. For the death analysis, the endpoint was the
time of death or was censored at the last time observed alive. For
the combined HIV transmission or death analysis, the endpoint
was estimated HIV-transmission time, or death time (if not HIV
infected), or was censored at the last negative test result.
In addition, we stratified the HIV-transmission rates by selected
variables of interest, including study period (i.e., before or after the
introduction of NFV in July 2005), infant gender, maternal baseline
CD4 count and viral load, and maternal regimen for those with
maternal baseline CD4 counts $250 cells/mm
3.W ep e r f o r m e dl o g -
rank tests to compare the survival curves obtained in these stratified
analyses over the 2-y follow-up period. We also used normal
approximation methods to compare differences between the Kaplan-
Meier estimates of the stratified HIV-transmission rates at 24 mo.
Finally, we calculated relative risks (RRs) with 95% CIs to determine
whether hepatotoxicity and rash SAEs were associated with baseline
maternal CD4 counts (,250 and $250 cells/mm
3) among the 310
women whose initial triple-ARV regimen included NVP.
Results
Between July 2003 and November 2006, we screened 602 HIV-
positive women, recruited from antenatal PMTCT clinics; 522
(87%) met eligibility criteria and were enrolled (Figure 1). The
main reasons for ineligibility included being over 36 wk gestation
(40%), Hb,7 gm/dl (12%), unable or unwilling to comply with
study procedures (18%), HIV negative on confirmatory testing
(9%), delivered before enrollment (8%), other abnormal laboratory
test (5%), and other reasons (8%). The median age of those
enrolled was 23 y (range 15–43 y) (Table 1). The median CD4
count was 398 cells/mm
3; 74 (14%) women had a CD4 count of
,200 cells/mm
3. NVP- or NFV-based triple-ARV prophylaxis
was initiated in 310 women and 212 women respectively.
A total of 511 infants were delivered, including nine sets of twins
and one set of triplets (Table 2). There were nine stillbirths (all
singletons), resulting in 502 live births (275 [57%] male, 227
[43%] female). No specimens were obtained from five infants (all
males) who died within 1 wk of delivery. Overall, 457 (91%), 427
Figure 1. Recruitment, enrollment, and follow-up of participating women and infants. KiBS, 2003–2009.
doi:10.1371/journal.pmed.1001015.g001
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12, and 24 mo, respectively (Figure 1). There were 491 live-born
singletons and first borns.
Transmission Rates
Among the 487 infants whoeverhad an HIVtest,12 had positive
delivery samples (0–7 d), consistent with a transmission rate of 2.5%
(1.4%–4.3%) (Table 3). An additional eight infections occurred by
6 wk for a cumulative transmission rate of 4.2% (2.7%–6.4%).
Cumulative transmission rates at 6, 12, 18, and 24 mo were 5.0%
(3.4%–7.4%), 5.7% (4.0%–8.3%), 6.7% (4.8%–9.4%), and 7.0%
(5.0%–9.7%), respectively (Figure 2). Among 491 singleton or first-
born infants, the death rates at 6, 12, 18, and 24 mo were 3.7%
(2.4%–5.9%), 8.9% (6.7%–11.9%), 10.0% (7.6%–13.1%), and
10.4% (8.0%–13.6%), respectively. Likewise, among these 491
infants, the combined HIV-transmission or death rates at 6, 12, 18,
and 24 mo were 8.5% (6.3%–11.4%), 13.5% (10.7%–16.9%),
15.3% (12.3%–18.9%), and 15.7% (12.7%–19.4%), respectively.
Conversely,HIV-free survivalat24 mowas84.3%(80.6%–87.3%).
Over the 2-y period from birth to 24 mo, the log-rank test shows
a significant difference in overall HIV transmission when stratified
by maternal baseline viral load categories (,10,000, $10,000
copies/ml, [p=0.03]), but no significant differences in the overall
HIV-transmission rates when stratified by study period (p=0.53),
maternal baseline CD4 count categories (,500 cells/mm
3, $500
cells/mm
3,[ p=0.10]), and infant sex (p=0.19), and by initial drug
regimen among mothers with baseline CD4 count $250 cells/mm
3
(p=0.96), although for many of these variables the magnitude of
difference increases gradually over the follow-up period (Table 4).
Focusing specifically on differences at 24 mo, HIV-transmission
rates were 4.3 percentage points (20.1 to 5.7 percentage points)
higher among infants whose mothers had baseline CD4 counts
,500 cells/mm
3 than those who had baseline CD4 counts $500
cells/mm
3 (p=0.06). No difference was detected in 24-mo HIV-
transmission rates when using a CD4 cutpoint of 350 cells/mm
3
(p=0.30). Likewise, at 24 mo, HIV-transmission rates were 5.7
percentage points (0.3–9.4 percentage points) higher among infants
whose mothers had baseline viral loads $10,000 copies/ml than
those who had baseline viral loads ,10,000 copies/ml (p=0.01).
Maternal Adverse Events
Of the 522 enrolled women, 66 (12.6%) had at least one ARV
substituted between enrollment and 9 mo post partum (Table 5),
including 42 of 310 (13.5%) women initially given NVP and 26 of
522 (5.0%) women initially given ZDV. Of these 66 women, 53
(80%) had an ARV-related SAE, and 13 (20%) had an illness that
required treatment incompatible with NVP (e.g., rifampicin for
tuberculosis, warfarin for anticoagulation). One participant had
NFV substituted due to neutropenia. Most SAEs were due to
common causes of morbidity in this region and HIV-related
opportunistic infections (e.g., malaria, tuberculosis). SAEs most
likely associated with study ARVs included anemia, neutropenia,
hepatotoxicity, and rash. Grade 3 or 4 anemia (Hb,7.0 g/dl) and
neutropenia (neutrophil count ,750 cells/ml measured on two or
more consecutive visits), occurred among 31 and 36 participants,
respectively, and nine participants had both. The Hb concentra-
tion among most participants increased over time: Hb#10.0 g/dl
for 58% at baseline and 9% at 9 mo post partum. In most cases
the neutropenia resolved without substitution of ARVs. Overall,
22 of 522 (4.2%) participants required ARV substitution because
of anemia and/or neutropenia (Table 5). Hepatotoxicity ($grade
2) SAEs occurred among 33 participants. Of the 14 with grade 3
or 4 hepatotoxicity, 12 were participants taking NVP. Among
participants who initially received NVP, grade 3 or 4 hepatotox-
Table 1. Maternal baseline sociodemographic, clinical, and
laboratory characteristics.
Variable (n=522) Category
Number (%) or
Median (Range)
Ethnic group Luo 447 (86%)
Luhya 54 (10%)
Other 21 (4%)
Median age (y) (n=520) 23 (15–43)
Primigravid Yes 130 (25%)
No 392 (75%)
Median parity, among
multigravid (n=392)
2 (0–8)
Marital status Single 69 (13%)
Married 388 (74%)
Separated 26 (5%)
Widowed 39 (8%)
Living with child’s father
(n=521)
Yes 376 (72%)
No 145 (28%)
Completed primary education
(8 y)
Yes 368 (70%)
No 154 (30%)
Employed outside home Yes 174 (33%)
No 348 (67%)
Median n people in household
(n=521)
3 (1–14)
Access to water (n=520) Piped to house 26 (5%)
Public tap 401 (77%)
Well, borehole 59 (11%)
River, lake, rain 34 (7%)
Toilet facility Private/shared flush
toilet
60 (11%)
Pit, latrine, bush 462 (89%)
Hb (g/dl) (n=520) 9.8 (7.0–13.9)
Median viral load (copies/ml)
(n=520)
33,975 (0–2.9 million)
Viral load (copies/ml) (n=520) Undetectable
(,400)
27 (5%)
400–9,999 120 (23%)
10,000–49,999 151 (29%)
$50,000 222 (43%)
Median CD4 count (cells/mm
3)
(n=520)
398 (32–1,340)
CD4 count (cells/mm
3)( n=520) ,200 74 (14%)
200–349 130 (25%)
350–499 144 (28%)
$500 172 (33%)
WHO clinical HIV disease stage Stage 1 439 (84%)
Stage 2 45 (9%)
Stage 3 or 4 38 (7%)
Initial triple-ARV regimen ZDV/3TC plus NVP 310 (59%)
ZDV/3TC plus NFV 212 (41%)
Percentages were computed excluding individuals with missing data for that
particular characteristic. n=522 unless stated.
doi:10.1371/journal.pmed.1001015.t001
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of $250 cells/mm
3 versus three of 114 (3%) women with CD4
count of ,250 cells/mm
3 (RR=1.7, 95% CI 0.5–6.3). There
were 16 rash SAEs, six with concomitant hepatotoxicity; all
occurred among women on NVP. Rash SAEs occurred in 12 of
196 (6%) women with a baseline CD4 count of $250 cells/mm
3
(including three cases of Stevens-Johnson Syndrome, all with CD4
counts of .350 cells/mm
3) versus four of 114 (4%) women with
CD4 counts of ,250 cells/mm
3 (RR=1.7, 95% CI 0.6–5.3). All
rash SAEs resolved after cessation of NVP. Of 12 maternal deaths
(five before 9 mo), nine were attributed to opportunistic infections
and three to progression of preexisting cardiac disease. No deaths
were attributed to ARVs.
Infant Adverse Events
The most common causes of child SAEs included diarrhea,
malaria, pneumonia, and anemia. Of the 146 reported diarrhea
SAEs, 86 (59%) occurred between the 5- and 9-mo study visits
(peri-weaning period). By 24-mo 49 (10%) of first-born children
had died (two additional deaths occurred among second-born
children); 42 (86%) deaths occurred during the first year of life.
The three most frequent causes of death were diarrhea (35%),
pneumonia (16%), and respiratory failure (12%). Twelve deaths
due to diarrhea occurred during the peri-weaning period and thus
could be attributed to early weaning; two of these infants were
HIV positive. No child deaths or other SAEs were clearly
attributable to maternal or child ARVs.
Table 2. Maternal and infant delivery characteristics.
Variable (n=500) Category n (%) or Median (Range)
Location of delivery Hospital
a 392 (78%)
Other health facility 22 (4%)
Participant’s home 45 (9%)
TBA home 30 (6%)
Other/unknown 11 (2%)
Median gestation (wk) 39 (33–48)
Gestation (wk) ,37 72 (14%)
37–42 355 (71%)
.42 73 (15%)
Median no. days on ARVs at delivery (n=498) 39 (1–100)
Days on ARVs at delivery (n=498) ,28 d 130 (26%)
$28 368 (74%)
Median viral load at delivery (copies/ml) (n=497) 87 (0–1.1 million)
Viral load at delivery (copies/ml) (n=497) Undetectable (,400) 333 (67%)
400–9,999 132 (27%)
10,000–49,999 11 (2%)
$50,000 21 (4%)
Infants delivery characteristics (n=511)
Infant status Live births 502
Stillbirths 9 (all singletons)
Singletons 481
Twins 18 (9 sets)
Triplets 3 (1 set)
Infant sex Female (8 stillbirths) 235 (46%)
Male (1 stillbirth) 276 (54%)
Delivery method (n=511) Spontaneous vertex 386 (76%)
Breech 8 (2%)
Cesarean delivery 41 (8%)
Other/unknown 76 (15%)
Median infant birth weight (g) (n=493) 3,000 (1,000–4,700)
Infant birth weight (g) (n=493) ,2,500 48 (10%)
$2,500 420 (90%)
Percentages were computed excluding individuals with missing data for that particular characteristic.
aNew Nyanza Provincial General Hospital and Kisumu District Hospital.
TBA, traditional birth attendant.
doi:10.1371/journal.pmed.1001015.t002
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Of the 522 enrolled participants, 439 (84%) took triple-ARV
prophylaxis through 6 mo post partum, whereas 83 (16%) stopped
prematurely due to withdrawal (56%), infant death/stillbirth
(19%), breastfeeding cessation (7%), maternal death (5%),
noncompliance with drugs/study visits (5%), and other reasons
(7%). Among participants on study at 6 mo, 82% (359/439) were
$95% adherent to the study ARVs. Of those participants with
viral load testing results, 5% (27/520) at enrollment, 67% (333/
497) at delivery, and 80% (348/435) at 6 mo post partum had an
undetectable viral load (defined as ,400 RNA copies/ml). Among
the 333 participants with an undetectable viral load at delivery,
88% (263/298) at 14 wk and 89% (258/294) at 6 mo post partum
(79% [227/288] at both times) had an undetectable viral load.
Among live-born infants, 98% (494/502) received a single dose
of NVP at delivery. Mixed feeding before 5 mo was documented
for 22% (109/502) of live-born infants. The triplets were never
breastfed but were provided formula. Of the HIV-negative infants
on study at 6 mo, 87% (379/434) reportedly had stopped
breastfeeding by 6 mo, in accordance with study recommenda-
tions. Nine infants who tested HIV negative at 6 mo subsequently
became HIV infected; none of their mothers, who had been
Table 3. Kaplan-Meier estimates of rates of HIV transmission and infant death.
HIV Transmission (n=487) Infant Death (n=491) Combined Outcome (n=491)
Age Events Rate 95% CI Events Rate 95% CI Events Rate 95% CI
7 d 12 2.5 (1.4–4.3) 7 1.4 (0.7–3.0) 19 3.9 (2.5–6.0)
14 d 14 2.9 (1.7–4.8) 9 1.8 (1.0–3.5) 23 4.7 (3.1–7.0)
30 d 19 3.9 (2.5–6.1) 9 1.8 (1.0–3.5) 28 5.7 (4.0–8.2)
42 d 20 4.2 (2.7–6.4) 11 2.3 (1.3–4.0) 31 6.4 (4.5–8.9)
2 m 20 4.2 (2.7–6.4) 11 2.3 (1.3–4.0) 31 6.4 (4.5–8.9)
3 m 22 4.6 (3.0–6.9) 12 2.5 (1.4–4.3) 34 7.0 (5.0–9.6)
4 m 22 4.6 (3.0–6.9) 14 2.9 (1.7–4.8) 36 7.4 (5.4–10.1)
6 m 24 5.0 (3.4–7.4) 18 3.7 (2.4–5.9) 41 8.5 (6.3–11.4)
9 m 26 5.5 (3.8–8.0) 35 7.4 (5.4–10.1) 58 12.2 (9.6–15.5)
12 m 27 5.7 (4.0–8.3) 42 8.9 (6.7–11.9) 64 13.5 (10.7–16.9)
18 m 31 6.7 (4.8–9.4) 47 10.0 (7.6–13.1) 72 15.3 (12.3–18.9)
24 m 32 7.0 (5.0–9.7) 49 10.4 (8.0–13.6) 74 15.7 (12.7–19.4)
Kaplan-Meier estimates of the cumulative rates of HIV transmission, infant death, and combined HIV transmission or death at selected ages, from birth to 24 mo, KiBS,
2003–2009. Data are infant ages (in days or months), cumulative events (counts), and Kaplan-Meier estimates of various rates (%) with 95% CIs.
doi:10.1371/journal.pmed.1001015.t003
Figure 2. Kaplan-Meier estimates of HIV-transmission rates. Kaplan-Meier estimates of HIV-transmission rates among live-born singletons and
first-born infants of mothers who received triple-ARV prophylaxis between 34 wk gestation and 6 mo post partum with 95% CIs.
doi:10.1371/journal.pmed.1001015.g002
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When probed about possible causes of infection only two of these
mothers acknowledged breastfeeding their infants beyond 6 mo.
Discussion
Transmission Rates and Comparison to Other Trials
The KiBS achieved 6-wk and 18-mo HIV-transmission rates of
4.2% and 6.7%, respectively. These rates are less than half the
corresponding HIV-transmission rates of 11.8% and 15.7%
observed in the HIVNET 012 study [8] conducted in Uganda,
using single-dose maternal and infant NVP. Likewise, KiBS
achieved a 4-mo transmission rate of 4.6%, a 77% reduction
compared with the corresponding rate of 19.9% reported in a
study of the impact of maternal malaria on perinatal HIV
transmission [19], conducted in Kisumu between 1996 and 2001
without a PMTCT intervention. Several studies have reported
comparable 6-mo HIV-transmission rates to that of KiBS (5.0%
[3.4%–7.4%]). MITRA Plus [20] in Tanzania, which provided
maternal ZDV, 3TC, and either NVP or NFV during late
pregnancy through 6 mo of breastfeeding (infants received
ZDV+3TC for 1 wk after birth), reported a 6-mo transmission
rate of 5.0% (3.2%–7.0%). Two recently completed randomized
trials also reported similar transmission rates in the arms
comparable to KiBS. In one arm of the BAN study in Malawi
[21], breastfeeding mothers with CD4 counts $250 cells/mm
3
and their infants received a short-course regimen including single-
dose NVP at birth and ZDV and 3TC for 7 d and then mothers
received a maternal triple-ARV regimen (Combivir and either
NVP or a protease inhibitor) for 28 wk. At 28 wk post partum the
transmission rate among all infants randomized to this arm was
8.2% (6.5%–10.3%). The Kesho Bora study [22] randomized
women at 28–36 wk gestation, with CD4 counts 200–500 cells/
mm
3 to either a triple-ARV regimen (ZDV+3TC+Lopinavir/
ritonavir [Kaletra, Abbott]) or a short ARV regimen (ZDV
through delivery plus single-dose NVP in labor). The 6-mo
transmission rate in the triple-ARV arm was 4.9% (3.1%–7.5%).
Two other studies using triple-ARV regimens have shown
somewhat lower rates. The AMATA study in Rwanda [23],
which provided maternal triple ARVs from 28 wk gestation and
for up to 6 mo of breastfeeding, reported a 9-mo transmission rate
of 1.8% (0.7%–4.8%). The Mma Bana study in Botswana [24],
which provided maternal triple ARVs from 28 to 34 wk gestation
through 6 mo of breastfeeding, reported a 6-mo transmission rate
of 1.1% (0.5%–2.2%).
In KiBS, 62.5% of the infant infections occurred by 42 d, i.e.,
primarily in utero or intrapartum. The median duration on ARVs
antepartum was 5.6 wk and 33% of tested participants had not
achieved undetectable viral load at delivery. The duration on
ARVs antepartum may explain some of the differences in
transmission rates seen in the PMTCT studies mentioned earlier.
The Mma Bana [24] and the AMATA study [23] reported median
duration on ARVs antepartum of 11 wk and 16.4 wk, respectively,
and both had 6-wk transmission rates #1.3%. Mitra Plus [20]
reported a median duration on ARVs antepartum of 5.4 wk and a
6-wk transmission rate of 4.1%, very similar to KiBS (4.2%).
Kesho Bora [22] reported 42.6% of the participants receiving
,6 wk of triple ARVs antepartum and a transmission rate of
3.3%. Given these findings and the transmission rates below 2% in
countries where triple-ARV prophylaxis is initiated during the
second trimester and where breastfeeding is avoided [25], it is
likely that initiating ARVs earlier during pregnancy in this study
Table 4. Stratified Kaplan-Meier estimates of HIV-transmission rates among live-born singletons and first-born infants.
Stratification
Variable Category n at Risk HIV-Transmission Rates (%) (95% CI)
Log-Rank
p-Value
Difference at
24-mo p-Value
Birth 6 mo 12 mo 18 mo 24 mo
Enrollment July 2003–Jan
2005
233 2.1 (0.9–5.1) 5.8 (3.4–9.7) 6.7 (4.1–10.9) 7.8 (4.9–12.2) 7.8 (4.9–12.2) 0.53 0.53
July 2005–Nov
2006
254 2.8 (1.3–5.7) 4.4 (2.5–7.8) 4.8 (2.8–8.4) 5.8 (3.5–9.6) 6.3 (3.8–10.2) — —
Maternal ,350 193 4.7 (2.5–8.8) 7.4 (4.4–12.1) 8.0 (4.9–12.8) 8.6 (5.3–13.6) 8.6 (5.3–13.6) 0.23 NA
Baseline 350–499 137 0.7 (0.1–5.1) 3.8 (1.6–9.0) 5.5 (2.7–11.2) 7.2 (3.8–13.4) 8.1 (4.4–14.5) — —
CD4 count $500 157 1.3 (0.3–5.0) 3.3 (1.4–7.7) 3.3 (1.4–7.7) 4.1 (1.8–8.8) 4.1 (1.8–8.8) — —
(Cells/mm
3) ,500 330 3.0 (1.6–5.6) 5.9 (3.8–9.1) 6.9 (4.6–10.3) 8.0 (5.5–11.6) 8.4 (5.8–12.0) 0.10 0.06
$500 157 1.3 (0.3–5.0) 3.3 (1.4–7.7) 3.3 (1.4–7.7) 4.1 (1.8–8.8) 4.1 (1.8–8.8) — —
Maternal ,400 27 3.7 (0.5–23.5) 3.7 (0.5–23.5) 3.7 (0.5–23.5) 3.7 (0.5–23.5) 3.7 (0.5–23.5) 0.21 NA
Baseline 400–9,999 112 0.9 (0.1–6.2) 1.9 (0.5–7.2) 2.8 (0.9–8.5) 2.8 (0.9–8.5) 2.8 (0.9–8.5) — —
Viral load 10,000–49,999 140 3.6 (1.5–8.4) 5.8 (2.9–11.3) 6.6 (3.5–12.3) 8.3 (4.7–14.6) 8.3 (4.7–14.6) — —
(Copies/ml) $50,000 206 2.4 (1.0–5.7) 6.5 (3.8–11.0) 7.1 (4.3–11.7) 8.3 (5.2–13.2) 8.9 (5.6–14.0) — —
,10,000 139 1.4 (0.4–5.6) 2.2 (0.7–6.7) 3.0 (1.1–7.8) 3.0 (1.1–7.8) 3.0 (1.1–7.8) 0.03 0.01
$10,000 346 2.9 (1.6–5.3) 6.2 (4.1–9.4) 6.9 (4.6–10.2) 8.3 (5.8–11.9) 8.7 (6.1–12.3) — —
Infant sex Female 223 3.1 (1.5–6.5) 6.5 (3.9–10.7) 7.6 (4.7–12.1) 8.7 (5.5–13.4) 8.7 (5.5–13.4) 0.19 0.21
Male 264 1.9 (0.8–4.5) 3.8 (2.1–7.0) 4.3 (2.4–7.6) 5.1 (3.0–8.7) 5.6 (3.4–9.3) — —
Initial regimen NVP-based 177 1.1 (0.3–4.4) 5.2 (2.8–9.8) 5.9 (3.2–10.6) 7.2 (4.2–12.4) 7.2 (4.2–12.4) 0.96 0.95
(CD4$250) NFV-based 196 3.1 (1.4–6.7) 4.7 (2.5–8.8) 5.3 (2.9–9.6) 6.5 (3.7–11.2) 7.1 (4.2–12.0) — —
Data are numbers of singleton or first-born (in a multiple birth) infants initially at risk in each stratification category, Kaplan-Meier estimates of HIV-transmission rates (%)
with 95% CIs at selected time points, p-values for the log-rank test, and, for stratification variables with two levels, two-sided p-values for the test of difference at 24 mo.
doi:10.1371/journal.pmed.1001015.t004
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However, timely initiation of ARVs may be a challenge in areas
where many women present late for antenatal care. A 2002 study
of recently delivered women in rural western Kenya showed that
64% first visited the antenatal clinic in the third trimester [26].
The cumulative transmission between 6 wk and 24 mo,
probably attributable to breastfeeding, was 3.2% (95% CI
1.9%–5.5%). Nine infants became infected after 6 mo post
partum. We probed the mothers for possible mechanisms of late
infection; seven of them denied any breastfeeding beyond 6 mo,
two infants underwent a traditional scarring procedure, and no
mothers reported premastication of food or breastfeeding by other
women (neither of these practices was common among KiBS
participants). Thus, unreported continued breastfeeding remains
the most likely mechanism of late infection. Cessation of
breastfeeding may have been difficult because of insufficient
resources, fear of stigma and unintentional disclosure, and the
tradition of breastfeeding well beyond 6 mo. Family support and
cultural norms, which are important to a mother’s decision about
when to stop breastfeeding, should be considered when promoting
early cessation of breastfeeding [27]. Rapid weaning may also
have contributed to infant HIV infection because of its association
with elevations in breast milk HIV levels and mastitis, as observed
in the Zambia Exclusive Breastfeeding Study [28]. The revised
WHO treatment criteria recommend treatment for those with
CD4 counts ,350 cells/mm
3 or WHO stage 3 or 4. Whereas we
observed lower 24-mo HIV-transmission rates among infants
whose mothers had higher CD4 count levels ($500 cells/mm
3),
we did not find any differences in infant transmission rates for
those with maternal baseline CD4 counts between 350–499 cells/
mm
3 and those with CD4 counts ,350 cells/mm
3.
The rates of infant HIV transmission or death at 6, 12, and
18 mo in KIBS were 8.5% (6.3%–11.4%), 13.5% (10.7%–16.9%),
and 15.3% (12.3%–18.9%), respectively. These rates are similar to
those reported at the same time points in MITRA Plus [20],
namely 8.6% (6.0%–11.2%), 12.8% (9.6%–16.0%), and 13.6%
(10.3%–16.9%). By comparison, the rate of HIV transmission or
death at 18 mo in HIVNET 012 [8] was 20.7% (16.2%–23.8%).
Although the study met the objective of a 50% reduction in
transmission compared to HIVNET 012 historic data, a
corresponding reduction in the combined endpoint of transmission
or death was not achieved. The failure to achieve this latter
reduction may reflect differences in study location, population, and
access to medical care among other possible factors.
Adherence and Adverse Events
The KiBS study intervention appeared well tolerated and safe.
Most (84%) of those enrolled took ARVs until 6 mo post partum,
even though most did not meet treatment criteria for themselves.
The implications of initiating triple ARVs when not needed for
their own health and then stopping ARVs after several months
require further study. Women who participated in this trial are
currently being enrolled into a study to evaluate their subsequent
response to ARV treatment. The development of ARV resistance
among infants is reported elsewhere in this issue [29]. Of those
who completed the intervention, 82% were $95% adherent.
Table 5. Maternal SAEs during intervention period (enrollment to 9 mo post partum), number resulting in ARV substitution, and
proportion of women initiated on ARV who required substitution.
Serious Adverse Event
Total n Women
with SAE (n=522)
Numberof Women
Requiring an ARV
Substitution for
Each SAE/Illnessa Number of Maternal ARV Substituted (%)
NVP (n=310) ZDV (n=522) NFV (n=212)
Potentially ARV-
related
Neutropenia 36 5 0 4 (0.8%) 1 (0.5%)
Anemia 31 14 0 14 (2.7%) 0
Anemia and neutropenia 9 3 0 3 (0.6%) 0
Hepatotoxicity
b 27 17 15 (4.8%) 2 (0.4%) 0
Rash 10 8 8 (2.6%) 0 0
Hepatotoxicity and rash
c 6 6 6 (1.9%) 2 (0.4%) 0
Illness requiring
ARV change
TB treatment
d 13 10 10 (3.2%) 1 (0.2%) 0
DVT treatment 2 2 2 (0.6%) 0 0
Hyperbilirubinemia 2 1 1 (0.3%) 0 0
Other SAEs Malaria 23 0 — — —
Pneumonia 7 0 — — —
Death 6 0 — — —
Gastroenteritis 3 0 — — —
Other 19 0 0 0 0
Total 194 66 42 (13.5%) 26 (5%) 1 (0.5%)
aEach participant only reported once for primary reason for ARV substitution between enrollment and 9-mo post partum.
bIncludes one participant where SAE attributed to ZDV, but stopped all ARVs.
cIncludes two participants who stopped both NVP and ZDV.
dIncludes one participant who stopped both NVP and ZDV.
DVT, deep venous thrombosis.
doi:10.1371/journal.pmed.1001015.t005
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for most women whose viral load was suppressed at delivery,
suppression was maintained at 6 mo post partum. There were no
unexpected ARV-related SAEs, although infant gastroenteritis
SAEs increased during the weaning period. The rates of NVP- and
ZDV-related SAEs were generally consistent with those reported
in the prescribing information from the drug manufacturers
[17,18], although we did not find a significant increase in NVP-
related hepatotoxicity and rash among mothers with CD4 counts
above 250 cells/mm
3 as had been reported in nonpregnant
women in other trials. Our findings are consistent with findings
from a recent analysis of HIV-infected pregnant women on ARVs
[30] in the US where a significant differential by CD4 count was
likewise not evident. Observed neutropenia was attributed
primarily to lower normal physiologic levels for African women
[31]; the use of US-based toxicity tables may have resulted in
overestimation of neutropenia-related SAEs.
Advantages
One advantage of this study was the use of a simple regimen
that did not require different drugs at different time points in the
pregnancy-delivery-breastfeeding continuum, and which could be
provided to all HIV-infected women regardless of CD4 count. In
many resource-limited settings one may not have the time to wait
for a CD4 count before deciding what regimen to start for
PMTCT. While the study regimen was changed in response to
concerns about NVP toxicity, our subsequent analysis shows that
women with higher CD4 counts on NVP treatment are not at
increased risk compared to women with lower CD4 counts.
Limitations
A limitationof this study is the lack of a concurrentcontrolgroup.
This decision was based on cost constraints and anticipated
difficulty in enrolling adequate numbers for a randomized trial.
Another limitation impacting the generalizability of this study
includes the intensity of visits, particularly during the intervention
period. The Kenya Ministry of Health currently schedules
vaccinations and vitamin A dosing in children #2 y of age at birth,
6, 10, and 14 wk, and 6, 9, 12, 18, and 24 mo [32]. The study visit
schedule was initially designed to follow the vaccination schedule
with only two additional visits at 2 wk and 15 mo. We modified the
protocol in2005,addingvisits at 5,7,and 8 mobecause of concerns
about the increased incidence of diarrhea during the peri-weaning
period. These visits focused on infant feeding, weight, and health.
No testing for HIV was done at the 10-wk, and 5-, 7-, and 8-mo
visits. Other limitations include the difficulty in accurately assessing
gestational age, the predominantly urban population, participant
self-selection bias, and possibility that some participants may have
given socially desirable responses to questions about adherence to
ARVs or infant feeding recommendations because of the strong
emphasis on these issues by study staff.
Summary
The KiBS demonstrates the feasibility and safety of the use of
triple-ARV prophylaxis from 34–36 wk gestation through 6 mo of
breastfeeding for PMTCT and achieved low transmission rates
among HIV-positive women who choose to breastfeed in Kisumu,
Kenya, a resource-limited setting. This study reinforces the findings
of other similar trials. The study findings were presented at the
WHO expert consultation on new and emerging evidence on the
use of ARV drugs for PMTCT in November 2008 [33] and have
added to the body of evidence supporting the recent WHO
guidelines [34], which recommend either the mother receiving
triple ARVs or the infant receiving ARV prophylaxis. Further
studies are still needed to determine the most appropriate strategies
and optimal length of breastfeeding; these questions are being
considered in the large PROMISE study (NIH/IMPAACT) [35].
Promoting HIV testing among pregnant women and expectant
fathers and ensuring that those who test positive receive effective
and timely PMTCT services and treatment remains a critical
worldwide challenge; however, the demonstration of effective
interventions now provide greater leverage for women to test and
enroll into PMTCT programs. In addition, the greater availability
of ARVs, especially combination pills that simplify regimens, vastly
improves the prospects for widespread implementation of triple
ARVs during pregnancy and breastfeeding for PMTCT in sub-
Saharan Africa, the heart of the current AIDS pandemic.
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Background. Every year, about half a million children
become infected with human immunodeficiency virus (HIV),
which causes acquired immunodeficiency syndrome (AIDS).
Nearly all these newly infected children live in resource-
limited countries and most acquire HIV from their mother,
so-called mother-to-child transmission (MTCT). Without
intervention, 25%–50% of babies born to HIV-positive
mothers become infected with HIV during pregnancy,
delivery, or breastfeeding. This infection rate can be
reduced by treating mother and child with antiretroviral
(ARV) drugs. A single dose of nevirapine (a ‘‘non-nucleoside
reverse transcriptase inhibitor’’ or NNRTI) given to the
mother at the start of labor and to her baby soon after
birth nearly halves the risk of MTCT. Further reductions in risk
can be achieved by giving mother and baby three ARVs—an
NNRTI and two nucleoside reverse transcriptase inhibitors
(NRTIs such as zidovudine and lamivudine)—during preg-
nancy and perinatally (around the time of birth).
Why Was This Study Done? Breastfeeding is crucial for
child survival in poor countries but it is also responsible for
up to half of MTCT. Consequently, many researchers are
investigating how various ARV regimens given to mothers
and/or their infants during the first few months of life as well
as during pregnancy and perinatally affect MTCT. In this
single-arm trial, the researchers assess the feasibility and
safety of using a triple-ARV regimen to suppress the
maternal HIV load (amount of virus in the blood) from late
pregnancy though 6 months of breastfeeding among HIV-
positive women in Kisumu, Kenya, and ask whether this
approach achieves a lower HIV transmission rate than other
ARV regimens that have been tested in resource-limited
settings. In a single-arm trial, all the participants are given
the same treatment. By contrast, in a ‘‘randomized
controlled’’ trial, half the participants chosen at random are
given the treatment under investigation and the rest are
given a control treatment. A randomized controlled trial
provides a better comparison of treatments than a single-
arm trial but is more costly.
What Did the Researchers Do and Find? In the Kisumu
Breastfeeding Study (KiBS), HIV-infected pregnant women
took a triple-ARV regimen containing zidovudine and
lamivudine and either nevirapine or the protease inhibitor
nelfinavir from 34–36 weeks of pregnancy to 6 months after
delivery. They were advised to breastfeed their babies (who
received single-dose nevirapine at birth), and to wean them
rapidly just before 6 months. The researchers then used
Kaplan-Meier statistical methods to estimate HIV
transmission and death rates among 487 live-born infants
from delivery to 24 months. The cumulative HIV transmission
rate rose from 2.5% at birth to 7.0% at 24 months. The
cumulative HIV transmission or death rate at 24 months was
15.7%; no infant deaths were attributed to ARVs. At 24
months, 3.0% of babies born to mothers with a low viral load
were HIV positive compared to 8.7% of babies born to
mothers with a high viral load, a statistically significant
difference. Similarly, at 24 months, 8.4% of babies born to
mothers with low baseline CD4 cell counts (CD4 cells are
immune system cells that are killed by HIV; CD4 cell counts
indicate the level of HIV-inflicted immune system damage)
were HIV positive compared to 4.1% of babies born to
mothers with high baseline CD4 cell counts, although this
difference did not achieve statistical significance.
What Do These Findings Mean? Although these findings
are limited by the single-arm design, they support the idea
that giving breastfeeding women a triple-ARV regimen from
late pregnancy to 6 months is a safe, feasible way to reduce
MTCT in resource-limited settings. The HIV transmission rates
in this study are comparable to those recorded in similar
trials in other resource-limited settings and are lower than
MTCT rates observed previously in Kisumu in a study in
which no ARVs were used. Importantly, the KiBS mothers
took most of the ARVs they were prescribed and most
stopped breastfeeding by 6 months as advised. The intense
follow-up employed in KiBS may be partly responsible for
this good adherence to the trial protocol and thus this
study’s findings may not be generalizable to all resource-
limited settings. Nevertheless, they suggest that a simple
triple-ARV regimen given to HIV-positive pregnant women
regardless of their baseline CD4 cell count can reduce MTCT
during pregnancy and breastfeeding in resource-limited
setting.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001015.
N The accompanying PLoS Medicine Research article by Zeh
and colleagues describes the emergence of resistance to
ARVs in KiBS
N Information on HIV and AIDS is available from the US
National Institute of Allergy and Infectious Diseases
N HIV InSite has comprehensive information on all aspects of
HIV/AIDS
N Information is available from Avert, an international AIDS
charity, on many aspects of HIV/AIDS, including informa-
tion on children, HIV, and AIDS and on preventing mother-
to-child transmission of HIV (in English and Spanish)
N UNICEF also has information about children and HIV and
AIDS (in several languages)
N The World Health organization has information on mother-
to-child transmission of HIV (in several languages)
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